EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

19 Fluorine ‐ MRI Based Longitudinal Immuno‐Microenvironment‐Monitoring for Pancreatic Cancer

Wilfried Reichardt, Tabea Gewalt, Philipp Hafner, Steffen J Keller, Xun Chen, Asma Alrawashdeh, Yayu Li, Solène Besson iD, Stefan Fichtner-Feigl, Dominik von Elverfeldt, Huda Jumaa, Dietrich A Ruess iD

Journal of Magnetic Resonance Imaging · 2025

DOI: 10.1002/jmri.29589 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Magnetic Resonance Imaging, 2025. Verfasst von Wilfried Reichardt und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Physics, Department of Diagnostic and Interventional Radiology, Medical Center University of Freiburg, Faculty of Medicine, Unive…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Tumor Microenvironment, Fluorine-19 Magnetic Resonance Imaging, Magnetic Resonance Imaging. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Krebshilfe, Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pancreatic cancer has a poor prognosis. Targeting Kirsten Rat Sarcoma (KRAS) mutation and its related pathways may enhance immunotherapy efficacy. While in vivo monitoring of therapeutic response and immune cell migration remains challenging, Fluorine‐19 MRI ( 19 F MRI) may allow noninvasive longitudinal imaging of immune cells.

Purpose

Evaluating the potential of 19 F MRI for monitoring changes in the tumor immune microenvironment, in response to combined SHP2/MEK inhibition. Study Type Pre‐clinical animal study. Animal Model Murine genetically engineered pancreatic cancer model (N = 20, both sexes). Field Strength/Sequence 9.4‐T, two‐dimensional multi‐slice Rapid Acquisition with Relaxation Enhancement sequence. Intravenous injection of 19 F‐perfluorocarbon (PFC) nanoparticles. Assessment Upon tumor detection by conventional 1 H MRI screening, 19 F MRI was performed in mice 24 hours after PFC nanoparticle administration. Animals were randomly assigned to four treatment groups: allosteric Src‐homology‐2‐containing protein tyrosine phosphatase 2 (SHP2) inhibitor SHP099, the mitogen‐activated extracellular signal‐regulated kinase 1/2 (MEK1/2) inhibitor Trametinib, the combination of both, or a vehicle control (4 to 6 mice each group), administered every other day per oral gavage. 1 H and 19 F MRI was repeated 7 days and 14 days later. Pancreatic immune cell infiltrates were analyzed by flow cytometry and multiplex immunohistofluorescence (mIHF) upon sacrifice. Statistical Tests Independent t ‐tests and one‐way analysis of variance.

Results

19 F MRI revealed continuous decrease of PFC‐signals in tumors from vehicle controls (100%, 80%, and 74% on days 0, 7, and 14, respectively), contrasting with stable or increasing signals under KRAS‐pathway‐directed treatment. MEK inhibition showed 100%, 152%, and 84% and dual SHP2/MEK1/2 inhibition demonstrated signals of 100%, 134%, and 100% on days 0, 7, 14, respectively. mIHF analyses indicated CD11b + macrophages/monocytes as primary contributors to the observed 19 F MRI signal differences. Data Conclusion 19 F MRI might provide non‐invasive longitudinal estimates for abundance and spatial distribution of CD11b + macrophages/monocytes in pancreatic cancer. Evidence Level 1 Technical Efficacy Stage 2

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsTumor MicroenvironmentFluorine-19 Magnetic Resonance ImagingMagnetic Resonance ImagingAnimalsMiceMaleFemaleDisease Models, AnimalNanoparticlesFluorocarbonsPyrimidinonesPyridonesProtein Tyrosine Phosphatase, Non-Receptor Type 11Piperidines

Stichwörter der Autor:innen

19Fluorine‐MRIKRASimmuno‐microenvironment‐monitoringpancreatic cancer

Substanzen

FluorocarbonstrametinibPyrimidinonesPyridonesProtein Tyrosine Phosphatase, Non-Receptor Type 11Piperidines

Autor:innen und Institutionen

  • Division of Medical Physics, Department of Diagnostic and Interventional Radiology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany.
  • German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Department of General and Visceral Surgery, Center for Surgery, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

ORCID-Profile: Solène Besson, Dietrich A Ruess

Förderung

  • Deutsche Krebshilfe
  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Reichardt, W., Gewalt, T., Hafner, P., Keller, S. J., Chen, X., Alrawashdeh, A., Li, Y., Besson, S., Fichtner-Feigl, S., von Elverfeldt, D., Jumaa, H., & Ruess, D. A. (2025). 19 Fluorine ‐ MRI Based Longitudinal Immuno‐Microenvironment‐Monitoring for Pancreatic Cancer. Journal of Magnetic Resonance Imaging. https://doi.org/10.1002/jmri.29589

Vancouver

Reichardt W, Gewalt T, Hafner P, Keller SJ, Chen X, Alrawashdeh A, et al. 19 Fluorine ‐ MRI Based Longitudinal Immuno‐Microenvironment‐Monitoring for Pancreatic Cancer. Journal of Magnetic Resonance Imaging. 2025. doi:10.1002/jmri.29589

BibTeX
@article{Reichardt2025,
  author = {Reichardt, Wilfried and Gewalt, Tabea and Hafner, Philipp and Keller, Steffen J and Chen, Xun and Alrawashdeh, Asma and Li, Yayu and Besson, Solène and Fichtner-Feigl, Stefan and von Elverfeldt, Dominik and Jumaa, Huda and Ruess, Dietrich A},
  title = {19 Fluorine ‐ MRI Based Longitudinal Immuno‐Microenvironment‐Monitoring for Pancreatic Cancer},
  journal = {Journal of Magnetic Resonance Imaging},
  year = {2025},
  doi = {10.1002/jmri.29589}
}
Kostenlos starten →